Raymond James Financial
TPST icon

Raymond James Financial’s Tempest Therapeutics TPST Stock Holding History

Raymond James Financial’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-234
Closed -$1.59K – 6637
2025
Q2 		$1.59K Buy
+234
New +$1.66K ﹤0.01% 6465

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Raymond James Financial's TPST Position: Q3 2025 in Review

Raymond James Financial sold out of Tempest Therapeutics (TPST) in Q3 2025, closing a stake of 234 shares — an estimated $1.59K sold.

Raymond James Financial first reported a position in TPST in Q2 2025 and held it in 1 quarter. The position peaked at $1.59K in Q2 2025. 17 funds tracked by Wall St. Rank hold TPST as of Q3 2025.

  • Raymond James Financial reported no remaining Tempest Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 234 Tempest Therapeutics shares in Q3 2025, an estimated $1.59K.
  • Raymond James Financial first reported a position in Tempest Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Tempest Therapeutics position peaked at $1.59K in Q2 2025.
  • 17 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.